Zhao Y Q, Kinuta M, Abe T, Yao W B, Ubuka T
Department of Biochemistry, Okayama University Medical School, Japan.
Acta Med Okayama. 1995 Feb;49(1):35-42. doi: 10.18926/AMO/30413.
The effects of intraperitoneal administration of 2-(4-carboxy-D-gluco-tetrahydroxybutyl)thiazolidine-4-carboxylic acid (CGUA), a cysteine derivative conjugated with glucuronic acid, on total glutathione and total cysteine contents in rat tissues were investigated. Total glutathione (GSH and GSSG) and total cysteine (cysteine and cystine) were determined by a new method consisting of preparation of S-carboxymethylglutathione (CMSG) and S-carboxymethylcysteine (CMC), respectively, and subsequent analyses with an amino acid analyzer. CGUA was determined by a coloration method employing an acidic ninhydrin reagent. Total cysteine contents in liver, kidney and plasma rapidly increased to 2.3, 2.7 and 6.5 times the levels of the controls, respectively, after CGUA administration at a dose of 5 mmol/kg of body weight. Total glutathione content did not change significantly in the liver or blood except for the kidney with a significant increase during the first 1-h period after administration. CGUA content increased markedly in these tissues, especially in the kidney, and 30% of administered CGUA was excreted in urine within 2h. These results indicate that CGUA is converted into cysteine in vivo, suggesting the usefulness of this compound for protection of the kidney and the liver.
研究了腹腔注射2-(4-羧基-D-葡糖四羟基丁基)噻唑烷-4-羧酸(CGUA,一种与葡糖醛酸结合的半胱氨酸衍生物)对大鼠组织中总谷胱甘肽和总半胱氨酸含量的影响。总谷胱甘肽(GSH和GSSG)和总半胱氨酸(半胱氨酸和胱氨酸)通过一种新方法测定,该方法分别包括制备S-羧甲基谷胱甘肽(CMSG)和S-羧甲基半胱氨酸(CMC),随后用氨基酸分析仪进行分析。CGUA通过使用酸性茚三酮试剂的显色法测定。以5 mmol/kg体重的剂量给予CGUA后,肝脏、肾脏和血浆中的总半胱氨酸含量分别迅速增加至对照组水平的2.3倍、2.7倍和6.5倍。除肾脏在给药后的最初1小时内显著增加外,肝脏或血液中的总谷胱甘肽含量没有显著变化。这些组织中的CGUA含量显著增加,尤其是在肾脏中,并且给药的CGUA中有30%在2小时内随尿液排出。这些结果表明,CGUA在体内转化为半胱氨酸,提示该化合物对保护肾脏和肝脏有用。